Remove Gene Therapy Remove Life Science Remove Pharma Companies Remove Regulation
article thumbnail

4 Life Sciences Trends for 2023

XTalks

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

article thumbnail

The Unprecedented Growth of Cell and Gene Therapy (2021)

Cloudbyz

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59
article thumbnail

Italfarmaco’s Duvyzat Wins FDA Approval as First Nonsteroidal Treatment for All Genetic Variants of DMD

XTalks

Bettica said the company’s focus is to now “make Duvyzat available as a treatment for DMD management in the US as quickly as possible.” In November, the FDA extended its decision deadline by three months to allow extra time for regulators to review additional information submitted by Italfarmaco as part of a new drug application.

article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare. It’s much needed.

Drugs 130
article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

article thumbnail

A Reuters Pharma conversation with EY: smart reviewing and payment outcomes

pharmaphorum

A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My We looked at the areas of rare diseases, cell and gene therapy, vaccines – loads of different perspectives. Innovative offerings around market access. About the interviewees.